NCT01408043 · OUTCOME

Neutrophil Recovery in Super Mobilizers and Normal Mobilizers

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma · Source last updated 2019-06-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: K/ul
Interval / dispersion: Standard Deviation
Time frame: Up to 28 days post treatment

What was measured

Neutrophil recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg entered as the mean cell count of super mobilizers and normal mobilizers.

Analysis population: All participants that had some mobilization

Groups in this outcome

Treatment (Stem Cell Supermobilization)

Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Stem Cell Supermobilization)	24

Reported measurements

Supermobilizers

Analysis denominator · Participants

Group	Source count
Treatment (Stem Cell Supermobilization)	7

Values in K/ul · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Treatment (Stem Cell Supermobilization)	10.3	0.5	Not reported	Not reported	Not reported

Normal Mobilizers

Analysis denominator · Participants

Group	Source count
Treatment (Stem Cell Supermobilization)	17

Values in K/ul · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Treatment (Stem Cell Supermobilization)	10.2	0.7	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
0.5
value
10.3
denoms
counts
group Id
OG000
value
7
units
Participants
title
Supermobilizers
categories
measurements
group Id
OG000
spread
0.7
value
10.2
denoms
counts
group Id
OG000
value
17
units
Participants
title
Normal Mobilizers

denoms

counts
group Id
OG000
value
24
units
Participants

description

Neutrophil recovery in participants receiving greater than or equal to 8 and less than 8 x 10\^6 CD34+ cells/kg entered as the mean cell count of super mobilizers and normal mobilizers.

dispersion Type

Standard Deviation

groups

description
Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of \>= 8 x 10\^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =\< 2 x 10\^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician. plerixafor: Given SC filgrastim: Given SC etoposide: Given IV leukapheresis: Undergo apheresis
id
OG000
title
Treatment (Stem Cell Supermobilization)

param Type

MEAN

population Description

All participants that had some mobilization

reporting Status

POSTED

time Frame

Up to 28 days post treatment

title

Neutrophil Recovery in Super Mobilizers and Normal Mobilizers

type

SECONDARY

unit Of Measure

K/ul

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice